Atrium to focus on metabolic syndrome, nutrition research

Atrium Innovations Inc. (TSX: ATB), a recognized leading developer, manufacturer and marketer of professionally endorsed, science-based dietary supplements for the health and nutrition industry, today announced a multi-year commitment to nutrition research and to a comprehensive program focusing on metabolic syndrome.  This global effort will be conducted in collaboration with a strategic partner, the Institute of Nutraceuticals and Functional Foods (INAF).  The total current funding for related projects planned and in progress is over $5 million, and includes partial support from governmental agencies.

"We have always believed in the importance of research.  This investment provides further indication of the depth of our commitment," said Pierre Fitzgibbon, President and CEO.  "Applying a more sophisticated science-based approach to our whole spectrum of products, we have the ability to positively affect the quality of life of people by helping them maintain their health and prevent serious diseases."

Atrium's research involves gaining a better understanding of metabolic syndrome and investigating the impact of nutrition on the prevention and treatment of silent inflammation associated with this condition.  More specifically, its research will emphasize the health benefits of small fruits, the anti-inflammatory mechanisms of specific fish oil fractions in the prevention of cardiovascular disease, probiotics, and systemic enzyme therapy in the management of inflammation, and health promotion.

"We have a duty to ensure that health care professionals, their patients, and health-conscious consumers have access to safe and effective nutritional products," said Dr. Barry W. Ritz, Vice President, Scientific and Regulatory Affairs.  "We have aligned ourselves with a strategic academic partner to conduct the most comprehensive program of cutting-edge research on the role of nutritional therapies in managing metabolic syndrome."